(Q41141615)

27 September 2017

1 reference

title

Effects of androgens on haemostasis (English)

1 reference

27 September 2017

Winkler UH

1

1 reference

27 September 2017

1 July 1996

1 reference

27 September 2017

1 reference

27 September 2017

24

1 reference

27 September 2017

3

1 reference

27 September 2017

147-155

1 reference

Sex hormones and coronary disease: a review of the clinical studies

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Plasminogen and plasminogen activator assembly on the human endothelial cell

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Sex hormone levels in young Indian patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Plasminogen activator inhibitor in plasma is related to testosterone in men

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Effects of anabolic steroids on haptoglobin, orosomucoid, plasminogen, fibrinogen, transferrin, ceruloplasmin, alpha-1-antitrypsin, beta-glucuronidase and total serum proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Prophylactic antithrombotic therapy with stanozolol in patients with familial antithrombin III deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Transient ischemic attack in a patient with congenital protein-C deficiency during treatment with stanozolol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Anabolic/androgenic steroid abuse and thrombosis: is there a connection?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Androgen-induced enhancement of vascular reactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Factor VII activation and menopausal status

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Atherogenesis in transgenic mice expressing human apolipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Hormonal agents used in lowering lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2896%2982004-4

7 January 2021

10.1016/S0378-5122(96)82004-4

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8844628